Male Hypogonadism Market - Rise In Awareness about the Available Treatment Options And Increase in Incidence of Male Hypogonadism Are Major Factors That Drive the Growth of the Market
Hypogonadism in the male is a clinical condition in which the testes fail to produce sufficient testosterone, resulting in decreased development of muscle mass, loss of body hair growth, development of breast tissue and a lack of vocalization. Growth in the male hypogonadism market is due to increased prevalence and frequency of patients with testosterone deficiency, increased rates of infertility, and increased patient awareness of options for treating STDs according to certain campaigns conducted by governments. In addition, the risk of germs is very high in the elderly population and in obese and diabetic populations.
Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/1874
Key players have adopted product approval as their key strategy to cater to the changing needs of the industry. There is high competition among key players to launch innovative, technologically advanced products to increase their market share and serve the patients in a better way.
Major players operating in this market include
• AbbVie Inc.
• Allergan plc
• AstraZeneca plc
• Bayer AG
• Eli Lilly and Company Ltd.
• Endo International plc
• Merck & Co. Inc.
• Ferring Holding S.A.
• Finox Biotech
• IBSA Institut Biochimque SA
• Laboratoires Genevrier
• Teva Pharmaceutical Industries Ltd.
The increase in the elderly population and the occurrence of chronic lifestyle disorders (obesity and diabetes) are expected to further stimulate market growth. However, the high side effects of all testosterone products are expected to hamper the growth of the testosterone replacement therapy (TRT) segment in this market. Technology advancement is expected to provide new opportunities during the forecast period.
Make an Enquiry before Buy @ https://www.alliedmarketresearch.com/purchase-enquiry/1874
North America accounted for the majority of market share (more than three quarters) in 2015 and is expected to dominate throughout the forecast period. This is due to an increase in the population suffering from primary and secondary causes of hypogonadism and an increase in patient awareness of the usefulness of treatment options. The high adoption rate of high technology products and the presence of highly sophisticated medical infrastructure are expected to create new growth opportunities for key players in this market. Europe is expected to register the highest CAGR of 7.2% during the analysis period with an increase in the adoption of western lifestyle, an increase in unhealthy eating habits, and an increase in the population with hypogonadism. Growth of urbanization.
Key Findings of the Male Hypogonadism Market
• By drug therapy, gonadotropin and gonadotropin-releasing hormones therapy segment is projected to grow at the highest CAGR of 8.9% during the forecast period.
• Pituitary disorders segment is expected to grow at the CAGR of 3.2%.
• Injectables accounted for nearly half of the market share in 2015.
• North America accounted for majority of the share (more than three-fourths) in 2015, and is expected to remain dominant throughout the forecast period.
• U.S. accounted for the majority share in the North American market in 2015, and the Mexican market is expected to grow at the highest CAGR of 6.7%.
Access Full Summery @ https://www.alliedmarketresearch.com/male-hypogonadism-market
Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Male Hypogonadism Market - Rise In Awareness about the Available Treatment Options And Increase in Incidence of Male Hypogonadism Are Major Factors That Drive the Growth of the Market here
News-ID: 1598687 • Views: 224
More Releases from Allied Market Research
North America Geogrid Market 2020 Segmentation, Demand, Growth, Trend, Opportuni …
According to the report published by Allied Market Research, the North America geogrid market generated $282.0 million in 2019, and is estimated to reach $408.25 million by 2027, registering a CAGR of 7.0% from 2020 to 2027. The report offers an extensive analysis of changing market dynamics, key winning strategies, business performance, major segments, and competitive scenarios. Surge in infrastructure development activities across the U.S. and Mexico and superior physical properties
Intravenous Immunoglobulin (IVIG) Market 2020 In-Depth Analysis of Industry Shar …
Global intravenous immunoglobulin market accounted for $8,995 million in 2017, and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025. Immunoglobulin (Ig) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to Ig, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) finds
Asthma and COPD Drugs Market Is Expected to Witness a Steady Growth by 2026
"Asthma and COPD Drugs Market by Disease and Medication Class - Global Opportunity Analysis and Industry Forecasts, 2014-2022", projects that the global market for Asthma and COPD Drugs was valued at $38,960 million in 2015 and would reach $50,359 million by 2022, registering a CAGR of 3.7% from 2016 to 2022. Asthma segment dominated the market in 2015 and expected to continue its dominance throughout the forecast period. North America
Synthetic Biology Market in Global Industry by Top Companies, Type and Applicati …
Global Synthetic biology market is forecast to reach $38.7 billion by 2020, at a CAGR of 44.2% during the forecast period (2014 - 2020). Europe occupies largest share in the global market and would hold-on to its position throughout 2020. However, Asia Pacific is the fastest growing market with a CAGR of 46.4% from 2014 - 2020. Read Full Report @ https://www.alliedmarketresearch.com/synthetic-biology-market Synthetic biology is at a nascent stage and has recently
More Releases for Hypogonadism
Male Hypogonadism: North America to Remain Largest Market for Male Hypogonadism …
The report "Global Market Study on Male Hypogonadism: North America to Remain Largest Market for Male Hypogonadism during 2017 - 2026 ", has been prepared based on an in-depth market analysis with inputs from industry experts. Male hypogonadism is a condition in males wherein the testes depict a significantly reduced functioning level than normal. Reduction in rate of biosynthesis of the male sex hormones consequently results into male hypogonadism, which can
Male Hypogonadism Market Growth Contemplation By 2025
Global Male Hypogonadism Market: Snapshot Hypogonadism in males refers to a condition in the male body where the testes show a significantly reduced level of functioning than normal. The overall result of male hypogonadism is a reduction in the rate of biosynthesis of male sex hormones. This state is more commonly known as interrupted stage 1 puberty. Hypoandrogenism, or the low androgen or testosterone level in a male can vary in
Male Hypogonadism Market Poised to Reach $ 3,300 Mn by 2026
North America will continue to dominate the global male hypogonadism market, with more than one-third revenue share during the forecast period. In addition, revenues from the male hypogonadism market in North America will exhibit the fastest expansion through 2026, as compared to those from all the other regional segments comprised in the report. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative for the male hypogonadism market.
Male Hypogonadism Market Growth Bar Increases $3,233 Million In 2022
Male hypogonadism is a medical condition characterized by the inability of the testes to produce sufficient amount of testosterone, which is responsible for the development of secondary sexual characteristics. This results in underdevelopment of muscles, impaired growth of body hair, development of breast tissues, and lack of deepening of the voice. For More Info, Get Sample : http://bit.ly/2Day9tu The global male hypogonadism market was valued at $2,594 million in
Male Hypogonadism - Pipeline Review, H1 2017
ReportsWeb.com has announced the addition of the “Male Hypogonadism - Pipeline Review, H1 20172017” The report focuses on global major leading industry players with information such as company profiles, product picture and specification. Male hypogonadism is a condition in which the body doesn't produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann
Male Hypogonadism - Pipeline Review, H2 2017
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Male Hypogonadism - Pipeline Review, H2 2017”. Male hypogonadism is a condition in which the body doesn't produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Request For Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1246563 Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and